What is HC Wainwright’s Estimate for IPSEN FY2026 Earnings?

IPSEN (OTCMKTS:IPSEY) – Equities researchers at HC Wainwright reduced their FY2026 earnings estimates for IPSEN in a research report issued on Friday, July 31st. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $3.36 for the year, down from their prior estimate of $3.62. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $3.84 per share.

IPSEY has been the topic of several other reports. Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Jefferies Financial Group downgraded IPSEN to an “underperform” rating in a research note on Sunday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

IPSEN Stock Performance

IPSEN stock opened at $44.85 on Tuesday. The stock’s 50 day moving average is $45.79 and its 200 day moving average is $45.61. IPSEN has a twelve month low of $30.05 and a twelve month high of $51.10.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).